CurrentCignaPolicy N/A

Tobramycin Inhalation Solution Prior Authorization Policy

Defines prior authorization requirements for coverage of tobramycin inhalation solutions (TOBI, Kitabis, Bethkis) under Cigna-administered health benefit plans for CF and non-CF bronchiectasis indications, and who may prescribe. Applies to affected members of Cigna plans unless a client's plan differs.

Policy Summary

PayerCigna

PolicyTobramycin Inhalation Solution Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial revision (age requirement removed for non-CF bronchiectasis)

Effective DateN/A

Next Review DateMar 18, 2026

Key ActionPrior authorization is required; approvals are for 1 year for cystic fibrosis and non-CF bronchiectasis when criteria are met, and 1 month for continuation of therapy.

SourceLink

POLICY UPDATE CHANGES

Bronchiectasis, Non-Cystic Fibrosis: the requirement that the patient is ≥ 18 years of age was removed.

Generic to Bethkis was added to the policy.

3brands/generics listed

1 yrapproval duration (CF/non-CF)

1 moapproval duration (continuation)

NCapplicable state

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Tobramycin Inhalation Solution

Initial therapy — Cystic Fibrosis

Covered when ALL of the following are met

CF indication: Cystic Fibrosis. Approve for 1 year if the patient meets BOTH of the following (A and B): A) Patient has Pseudomonas aeruginosa in culture of the airway; AND B) The medication is prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis.

Examples of airway culture include sputum, oropharyngeal, or bronchoalveolar lavage culture.

Initial therapy — Non-CF Bronchiectasis

Covered when ALL of the following are met

Non-CF bronchiectasis indication: Bronchiectasis, Non-Cystic Fibrosis. Approve for 1 year if the patient meets BOTH of the following (A and B): A) Patient has Pseudomonas aeruginosa in culture of the airway; AND B) The medication is prescribed by or in consultation with a pulmonologist.

Age ≥18 requirement was removed per policy history; ERS guidelines support inhaled antibiotics for chronic P. aeruginosa in high-risk patients.

Continuation therapy — criteria for continued approval and duration

Covered when ALL of the following are met

Continuation of Tobramycin Inhalation Solution Therapy. Approve for 1 month if the patient was started on tobramycin inhalation solution and is continuing a course of therapy.

Intended to cover ongoing courses initiated prior to authorization period.

Tobramycin inhalation solution is not medically necessary for any use(s) not specified in this policy. This includes compounding or any off‑label preparations intended for intranasal or nasal rinse administration. Requests for coverage of tobramycin formulated as a nasal rinse (compounded or otherwise) are not approvable under this policy.

Use of tobramycin inhalation solution as a tobramycin nasal rinse (compounded nasal rinse) is explicitly not approvable / not medically necessary and will be denied.

Products, Codes, and Labeling Notes

Listed productsmixed

TOBI	tobramycin inhalation solution - Mylan (generic)
Kitabis	tobramycin inhalation solution - Pari (authorized generic)
Bethkis	tobramycin inhalation solution - Chiesi (generic)

Age & safety/efficacy labeling notes

Minimum age — TOBI/Kitabis/BethkisSafety and efficacy have not been demonstrated in patients < 6 years of age; TOBI and Kitabis indicated for patients ≥ 6 years.

Bethkis FEV1 labelingBethkis labeling: safety/efficacy not demonstrated in patients with FEV1 < 40% or > 80% predicted.

TOBI/Kitabis FEV1 labelingTOBI and Kitabis: safety/efficacy not demonstrated in patients with FEV1 < 25% or > 75% predicted.

Burkholderia cepacia colonizationSafety and efficacy not demonstrated in patients colonized with Burkholderia cepacia (all products noted).

Provider Requirements and Actions

Prior Authorization

Prior Authorization Required

Prior Authorization Required. All approvals are provided for the duration noted: 1 year for cystic fibrosis and non‑CF bronchiectasis when criteria are met; 1 month (30 days) for continuation of therapy.

Approval duration: 1 year for CF and non‑CF bronchiectasis when criteria met
Continuation approvals: 1 month = 30 days

Note

Specialist Prescribing Requirement

Prescriptions must be written by or in consultation with a specialist in the condition being treated. For cystic fibrosis this means a pulmonologist or a physician who specializes in CF; for bronchiectasis this means a pulmonologist.

Specialist requirement applies at initial approval and continuation where applicable
Documentation should reflect the specialist involvement (prescribing provider or documented consultation)

Documentation Required

Required Documentation: Airway Culture

Documentation of a positive airway culture for Pseudomonas aeruginosa is required. Acceptable specimen sources include sputum culture, oropharyngeal culture, and bronchoalveolar lavage culture. Ensure culture results are included in the request and clearly identify organism and specimen source.

Required: airway culture positive for Pseudomonas aeruginosa
Acceptable specimen sources: sputum, oropharyngeal swab, bronchoalveolar lavage (BAL)

Denial Risk

Denial Risk — Actionable Items to Avoid Denial

Claims lacking a covered diagnosis, missing required culture documentation, missing specialist prescribing/consultation evidence, or not billed with appropriate covered codes are subject to denial. Requests that do not meet the stated approval durations or that lack evidence of prior therapy for continuation may be denied.

Denial triggers: no covered diagnosis documented (CF or non‑CF bronchiectasis)
Denial triggers: no airway culture positive for Pseudomonas aeruginosa provided
Denial triggers: prescribing provider not a specialist and no documented consultation
Denial triggers: requests exceeding approval durations or lacking evidence for continuation

Background

Tobramycin inhalation solutions are aminoglycoside antibiotics indicated primarily for management of patients with cystic fibrosis who have airway infection with Pseudomonas aeruginosa. Product labeling and clinical guidance support chronic inhaled tobramycin for eligible patients; evidence also supports use in non‑cystic fibrosis bronchiectasis with chronic P. aeruginosa infection. Safety and efficacy have not been demonstrated in all age groups, and labeling provides age and lung‑function thresholds to guide appropriate use.

Policy Summary

PayerCigna

PolicyTobramycin Inhalation Solution Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial revision (age requirement removed for non-CF bronchiectasis)

Effective DateN/A

Next Review DateMar 18, 2026

Key ActionPrior authorization is required; approvals are for 1 year for cystic fibrosis and non-CF bronchiectasis when criteria are met, and 1 month for continuation of therapy.

SourceLink

On This Page

OpenPayer

Tobramycin Inhalation Solution Prior Authorization Policy

Coverage Criteria for Tobramycin Inhalation Solution

Products, Codes, and Labeling Notes

Provider Requirements and Actions

Definitions and Specimen Examples

Background

Revision History